Felix Feng
Overview
Explore the profile of Felix Feng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1638
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stress testing deep learning models for prostate cancer detection on biopsies and surgical specimens
Flannery B, Sandler H, Lal P, Feldman M, Santa-Rosario J, Pathak T, et al.
J Pathol
. 2024 Dec;
265(2):146-157.
PMID: 39660731
The presence, location, and extent of prostate cancer is assessed by pathologists using H&E-stained tissue slides. Machine learning approaches can accomplish these tasks for both biopsies and radical prostatectomies. Deep...
2.
Pommier P, Xie W, Ravi P, Carrie C, Dignam J, Feng F, et al.
Radiother Oncol
. 2024 Sep;
201:110532.
PMID: 39278317
Background: Early salvage radiotherapy (SRT) is the standard of care for biochemical recurrence post-prostatectomy but outcomes are heterogeneous. Objective: To develop a risk scoring system based on relevant standard-of-care clinico-pathological...
3.
Mohamad O, Li Y, Feng F, Hong J, Wong A, Kouzi Z, et al.
Prostate Cancer Prostatic Dis
. 2024 Aug;
PMID: 39128937
Delays in the work-up and definitive management of patients with prostate cancer are common, with logistics of additional work-up after initial prostate biopsy, specialist referrals, and psychological reasons being the...
4.
Sutera P, Deek M, Deek R, Guler O, Hurmuz P, Reyhan M, et al.
Adv Radiat Oncol
. 2024 May;
9(7):101507.
PMID: 38799104
Purpose: Emerging data suggest that metastasis-directed therapy (MDT) improves outcomes in patients with oligometastatic castration-sensitive prostate cancer (omCSPC). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can detect occult metastatic disease,...
5.
Weiner A, Kakani P, Armstrong A, Bossi A, Cornford P, Feng F, et al.
Eur Urol
. 2024 May;
86(3):200-210.
PMID: 38782697
Background And Objective: Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that...
6.
Brookman-May S, Buyse M, Freedland S, Miladinovic B, Zhang K, Fendler W, et al.
Eur Urol
. 2024 May;
86(2):81-87.
PMID: 38762392
Defining meaningful endpoints for research of early-stage high-risk prostate cancer is challenging, with established measures such as overall survival and metastasis-free survival facing limitations related to feasibility and adequate reflection...
7.
Yadav S, Jiang F, Kurkowska S, Saelee R, Morley A, Feng F, et al.
J Nucl Med
. 2024 May;
65(7):1064-1069.
PMID: 38724282
Understanding the relationship between lesion-absorbed dose and tumor response in Lu-PSMA-617 radiopharmaceutical therapies (RPTs) remains complex. We aimed to investigate whether baseline lesion-absorbed dose can predict lesion-based responses and to...
8.
James N, Tannock I, Ndow J, Feng F, Gillessen S, Ali S, et al.
Lancet
. 2024 Apr;
403(10437):1683-1722.
PMID: 38583453
No abstract available.
9.
Buyyounouski M, Pugh S, Chen R, Mann M, Kudchadker R, Konski A, et al.
JAMA Oncol
. 2024 Mar;
10(5):584-591.
PMID: 38483412
Importance: No prior trial has compared hypofractionated postprostatectomy radiotherapy (HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily treated with prostatectomy. Objective: To determine if HYPORT is noninferior to COPORT...
10.
Xu Y, Wang Z, Sjostrom M, Deng S, Wang C, Johnson N, et al.
bioRxiv
. 2023 Nov;
PMID: 37961351
Statement Of Significance: This study reveals a novel epigenetic mechanism regulating tumor lineage plasticity and therapy response, enhances understanding of drug resistance and unveils a new therapeutic strategy for prostate...